Low-Dose Tamoxifen for Noninvasive Breast Disease: A Meta-Analysis

Tamoxifen is a classic endocrine therapy for breast cancer; however, conventional doses of tamoxifen have serious side effects. Therefore, it is crucial to prioritise the treatment of low-dose tamoxifen. Databases were searched for related studies before November 23, 2023. The overall incidence of breast events, ipsilateral tumour events, and contralateral breast events decreased significantly in patients treated with low-dose tamoxifen. There was no significant difference in mortality from breast cancer (p = 0.767). However, mortality due to non-breast cancer causes was decreased statistically (p <0.001); the overall mortality rate reduced after taking low-dose tamoxifen (p = 0.002). There was no significant rise in the occurrence of endometrial cancer among individuals who received low-dose tamoxifen treatment (p = 0.577). The total incidence of adverse events did not increase at the same time (p = 0.216). For patients with noninvasive breast disease, low doses of tamoxifen can be chosen for prevention and treatment to reduce the risk of breast carcinoma.